# Semaglutide 2.4 mg cut exercise wedge pressure by 10.6 mmHg versus placebo in HFpEF, 81-patient trial

- Published: 2026-11-09 02:49 UTC
- Section: Life & Health › Medicine
- Tags: semaglutide HFpEF, pulmonary capillary wedge pressure, exercise haemodynamics, GLP-1 receptor agonist, CAMEO-SEMA, NCT05371496, left atrial reservoir strain, Nature Medicine, haemodynamic remission
- URL: https://realtech.media/news/rt-a351fe2714e504faed9dc709_semaglutide_2_4/

**In a double-blind placebo-controlled trial of 81 patients with obesity and HFpEF, weekly semaglutide lowered pulmonary capillary wedge pressure during exercise over 52 weeks, authors report.**

![Semaglutide 2.4 mg cut exercise wedge pressure by 10.6 mmHg versus placebo in HFpEF, 81-patient trial](https://realtech.media/media/2026/11/b0979df02692992f.webp)
*ad-hoc-news.de*

A double-blind, placebo-controlled trial published in Nature Medicine reports that weekly semaglutide 2.4 mg lowered pulmonary capillary wedge pressure (PAWP) during exercise in people with heart failure with preserved ejection fraction (HFpEF) and obesity, according to ad-hoc-news.de. The study ran for 52 weeks and enrolled 81 patients, 47 of them women. It is registered as NCT05371496 on ClinicalTrials.gov and was also presented at the AHA Scientific Sessions 2026. [1]

## Invasive haemodynamics: exercise and resting PAWP

At baseline, mean exercise PAWP was 31.7 ± 5.2 mmHg and resting PAWP was 17.5 ± 4.3 mmHg. After one year, exercise PAWP changed by −9.8 mmHg (95% CI −11.3 to −8.2) in the semaglutide group and by +0.9 mmHg (95% CI −1.3 to 3.0) in the placebo group. The estimated difference was −10.6 mmHg (95% CI −13.3 to −8.0; P<0.0001). [1]

Resting filling pressure also fell: the difference in resting PAWP was −7.1 mmHg (95% CI −9.8 to −4.4; P<0.0001). Haemodynamic remission was reached by 53.7 percent of patients on semaglutide versus 7.4 percent on placebo, an odds ratio of 14.1 (95% CI 3.0–134.6; P<0.001). Reports from the meeting say other haemodynamic parameters improved on the drug as well. [1]

## Cardiac MRI substudy CAMEO-SEMA

The prespecified cardiac MRI substudy CAMEO-SEMA, registered under the same number, examined 49 participants: 33 on semaglutide and 16 on placebo, 28 of them women. MRI was performed at baseline and at 52 weeks, in each case within one day of the invasive exercise haemodynamics. [1]

For the primary MRI endpoint, left atrial reservoir strain rose by +5.7% versus placebo (95% CI +0.3 to +9.7; P=0.037). The eFR/EDV parameter improved by +0.64 s⁻¹ (95% CI +0.42 to +1.00; P<0.0001). [1]

Both MRI parameters were associated with the reduction in exercise PAWP, with correlations of r=−0.46 (P<0.001) and r=−0.65 (P<0.0001) respectively. Under semaglutide the investigators also found reduced left ventricular mass, a more physiological left ventricular geometry and improved right ventricular function. [1]

## Sources

1. [ad-hoc-news.de](https://www.ad-hoc-news.de/wissenschaft/semaglutid-bei-hfpef-studie-zeigt-10-6-mmhg-weniger-druck-unter-belastung/70478477)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-a351fe2714e504faed9dc709_semaglutide_2_4/